Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC grew its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 208.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 236,682 shares of the medical instruments supplier's stock after buying an additional 160,073 shares during the quarter. Natixis Advisors LLC owned about 0.08% of Becton, Dickinson and Company worth $57,064,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. WR Wealth Planners LLC grew its stake in Becton, Dickinson and Company by 1.4% in the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier's stock valued at $696,000 after acquiring an additional 42 shares during the last quarter. Clear Creek Financial Management LLC increased its stake in shares of Becton, Dickinson and Company by 5.1% during the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier's stock worth $210,000 after purchasing an additional 44 shares in the last quarter. Sound Income Strategies LLC raised its position in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier's stock worth $40,000 after purchasing an additional 44 shares during the last quarter. Central Pacific Bank Trust Division raised its position in shares of Becton, Dickinson and Company by 22.5% during the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier's stock worth $59,000 after purchasing an additional 45 shares during the last quarter. Finally, Tompkins Financial Corp lifted its stake in Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier's stock valued at $36,000 after buying an additional 46 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Down 0.9 %

Shares of NYSE BDX traded down $2.02 during trading on Friday, hitting $225.15. 1,965,697 shares of the company traded hands, compared to its average volume of 1,528,964. The firm has a market capitalization of $65.08 billion, a P/E ratio of 37.90, a P/E/G ratio of 1.68 and a beta of 0.43. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The company has a 50-day moving average price of $236.30 and a 200-day moving average price of $234.99. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $249.89.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the previous year, the business earned $3.42 earnings per share. The firm's quarterly revenue was up 6.9% compared to the same quarter last year. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be given a dividend of $1.04 per share. This is a boost from Becton, Dickinson and Company's previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.85%. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company's payout ratio is presently 63.97%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BDX. Raymond James cut their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an "outperform" rating for the company in a report on Friday, August 2nd. Evercore ISI upped their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Citigroup upgraded shares of Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a "buy" rating in a research note on Friday, July 26th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Thursday, August 8th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.